Results 71 to 80 of about 11,886 (196)

Pregnancy in PNH: another eculizumab baby. [PDF]

, 2010
Pregnancy in PNH: another eculizumab ...
Notaro R, Santachiara R, COLUCCIO, Valeria, TORELLI, Giuseppe, Leonardi G, Luzzatto L., MARASCA, Roberto   +6 more
core   +1 more source

Eculizumab for Shiga‐toxin‐induced hemolytic uremic syndrome in adults with neurological involvement

eJHaem
The role of eculizumab in treating Shiga‐toxin‐producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) patients with neurological involvement remains unclear.
Benjamin J. Lee, Zhaohui Arter, Jean Doh, Shawn P. Griffin, Pongthep Vittayawacharin, Steven Atallah, Kevin R. Shieh, Minh‐Ha Tran, Sonata Jodele, Piyanuch Kongtim, Stefan O. Ciurea   +10 more
doaj   +1 more source

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

Transplant Infectious Disease, EarlyView.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval, Mohamed Eltemamy, Nabin K. Shrestha, Leal Herlitz, Emilio D. Poggio, Alvin C. Wee   +5 more
wiley   +1 more source

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1%

American Journal of Hematology, Volume 101, Issue 9, Page 2311-2328, September 2026.
ABSTRACT The clinical significance of PNH Type II white blood cells (WBCs) remains unclear. We assessed the relative percentage (rel%) of Type II neutrophils in 355 patients with a PNH clone ≥ 1% on neutrophils enrolled by 33 flow cytometry laboratories in the 5‐year French nation‐wide multicenter prospective observational study.
Orianne Wagner‐Ballon, Anne‐Catherine Lhoumeau, Anna Raimbault, Camille Debord, Jean‐Philippe Vial, Valérie Soenen, Mélanie Pannetier, Edouard Bonneville, Elsa Bera, Caroline Bret, Nicolas Chapuis, Véronique Latger‐Cannard, Caroline Mayeur‐Rousse, Véronique Harrivel, François Vergez, Marie Loosveld, Juliette Vo Xuan, Stéphanie Mathis, Gérard Socié, Flore Sicre de Fontbrune, Régis Peffault de Latour, Bernard Drenou, Agathe Debliquis, Magali Le Garff‐Tavernier, on behalf of the French PNH working group CytHem‐HPN, Thomas Boyer, Mikaël Roussel, Marie Guillon, Sabrina Bouyer, Isabelle Kittler, Franck Geneviève, Julien Guy, Sophie Brun, Claude Capron, Sébastien Lachot, Francine Garnache‐Ottou, Richard Veyrat‐Masson, Corine Brunet, Caren Brumpt, Ludovic Lhermitte. Finally, Louis Terriou, Nicolas Blin   +41 more
wiley   +1 more source

Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment [PDF]

, 2017
Contains fulltext : 177003.pdf (Publisher’s version ) (Open Access) Contains fulltext : 177003pos.pdf (Author’s version postprint ) (Open Access)Recent studies indicate that ...
Wijnsma, K.L., Velden, T.J. van der, Goertz, J.H.C., Roeleveld, N., Heuvel, L.P. van den, Sweep, C.G.J., Kar, N.C. van de, Bruggemann, R.J.M., Volokhina, E.B., Wetzels, J., Molen, R.G. van der   +10 more
core   +1 more source

Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation

Kidney Medicine, 2019
Eculizumab is an emerging therapy for atypical hemolytic uremic syndrome (aHUS). Early identification and treatment of recurrent aHUS after kidney transplantation requires a high clinical suspicion but results in improved graft function and patient ...
Priyamvada Singh, Hui Chen, Craig E. Gordon, Sandeep Ghai, J. Mark Sloan, Karen Quillen, Sara Moradi, Vipul Chitalia, Amitabh Gautam, Joel Henderson, Jean M. Francis   +10 more
doaj   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. [PDF]

, 2006
Item does not contain fulltextBACKGROUND: We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal ...
Christopher F. Mojcik, Mojcik, C.F., Young, N.S., Antonio M. Risitano, Chieh-Lin Fu, Browne, P., Jörg Schubert, Luzzatto, L., Elebute, M.O., Maciejewski, J, Russell P. Rother, Fu, C.L., Jeffrey Szer, Socie, G., Hubert Schrezenmeier, Rollins, S.A., Anita Hill, Szer, J., Schrezenmeier, H., Modupe O. Elebute, Jaroslaw Maciejewski, Nakamura, R., Roth, A., Maciejewski, J.P., Alexander Röth, Rother, R.P., Brodsky, R.A., Gerard Socié, Lucio Luzzatto, Ryotaro Nakamura, Schubert, J., Paul Browne, Hillmen, P., Peter Hillmen, Hill, A., Petra Muus, Scott A. Rollins, Neal S. Young, Muus, P., Robert A. Brodsky, Risitano, A.M.   +40 more
core   +1 more source

Temperature Safeguards and Peri‐Procedural Strategies for Stem Cell Collection in Cold Agglutinin Disease: A Case Report and Literature Review

Journal of Clinical Apheresis, Volume 41, Issue 4, August 2026.
ABSTRACT Cold agglutinins can result in red blood cell (RBC) agglutination and lysis at low temperatures. Temperature sensitivity during stem cell mobilization, processing, and infusion poses unique procedural challenges in patients with active cold agglutinins.
S. Bellegarde, C. Scott, R. Sabol, T. Eunson, Z. J. Gahvari, C. P. Onyenekwu   +5 more
wiley   +1 more source

Continued Eculizumab Therapy for Persistent Atypical Hemolytic Uremic Syndrome [PDF]

, 2013
Atypical hemolytic uremic syndrome (atypical HUS) is characterized by endothelial injury and microvascular thrombosis resulting in microangiopathic hemolytic anemia, thrombocytopenia, and ischemic injury to organs, especially the kidney.
Vachharajani, Tushar, Mathew, Roy O, Haqqie, Syed S, Ghate, Ketan, Nayer, Ali, Asif, Arif   +5 more
core   +1 more source